title: Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.
abstract: Previously, replicating adenovirus type 5 host range (Ad5hr)-HIV/SIV recombinant priming in combination with SIV envelope boosting, resulted in significant, durable protection in 39% of rhesus macaques after SIVmac251 challenge. Both Env-specific antibody mediating ADCC, and cellular immunity correlated with protection. Here we evaluate the relative immunogenicities of novel HIV proteins and their contribution to protection in a SHIV89.6P model. All groups were primed with Ad-HIVenv89.6P, SIVgag239, and SIVnef239 recombinants. One group was not boosted, one received HIV89.6Pgp140DeltaCFI protein, and one a novel HIV-1 poly-peptide "peptomer". The HIV89.6Pgp140DeltaCFI protein in adjuvant strongly boosted Env-specific antibody and memory T cell responses in blood and tissue, resulting in significant reductions in acute and set point viremia. Macaques not boosted, showed a significant reduction in set point viremia, a full 32 weeks after the last Ad priming immunization. The HIV peptomer-boosted group showed a trend toward chronic viremia reduction, but was not protected.
authors.affiliation: Vaccine Branch, National Cancer Institute, Bethesda, MD 20892, USA.
authors.forename: L Jean
authors.initials: LJ
authors.lastname: Patterson
authors.forename: Jennifer
authors.initials: J
authors.lastname: Beal
authors.forename: Thorsten
authors.initials: T
authors.lastname: Demberg
authors.forename: Ruth H
authors.initials: RH
authors.lastname: Florese
authors.forename: Nina
authors.initials: N
authors.lastname: Malkevich
authors.forename: David
authors.initials: D
authors.lastname: Venzon
authors.forename: Kris
authors.initials: K
authors.lastname: Aldrich
authors.forename: Ersell
authors.initials: E
authors.lastname: Richardson
authors.forename: V S
authors.initials: VS
authors.lastname: Kalyanaraman
authors.forename: Irene
authors.initials: I
authors.lastname: Kalisz
authors.forename: Eun Mi
authors.initials: EM
authors.lastname: Lee
authors.forename: David C
authors.initials: DC
authors.lastname: Montefiori
authors.forename: Frank A
authors.initials: FA
authors.lastname: Robey
authors.forename: Marjorie
authors.initials: M
authors.lastname: Robert-Guroff
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology; D000256:Adenoviridae / Q000235:genetics / Q000502:physiology*; D000818:Animals; D005822:Genetic Vectors; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000517:prevention & control; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D007114:Immunization; D007117:Immunization, Secondary; D008253:Macaca mulatta; D008297:Male; D011995:Recombination, Genetic; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000276:immunology; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity / Q000528:radiation effects; D013601:T-Lymphocytes / Q000276:immunology; D014766:Viremia / Q000517:prevention & control*; D014779:Virus Replication; D054299:env Gene Products, Human Immunodeficiency Virus / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D015395:Histocompatibility Antigens Class I; C110764:Mamu-A 01 antigen; D018449:SAIDS Vaccines; D054299:env Gene Products, Human Immunodeficiency Virus; C097729:gp140 envelope protein, Human immunodeficiency virus 1